Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.

ABSTRACT:

Background and objectives

Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated.

Design, setting, participants, & measurements

Patients who attended the clinic were included prospectively from 1995 on. A crude incidence ratio for the occurrence of malignancy was calculated. Incidence ratios were subsequently standardized to potential confounders. Latency between cyclophosphamide therapy and the occurrence of cancer was estimated by stratifying for time since the start of treatment. Finally, Poisson regre

SUBMITTER: van den Brand JA 

PROVIDER: S-EPMC4046727 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature